Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM-1-104 in Advanced or Metastatic Solid Tumors
NCT05585320Phase 2Active, not recruiting
- Sponsor
- Immuneering Corporation
- Start
- Oct 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of atebimetinib in solid tumor, pancreatic adenocarcinoma (PDAC), melanoma, non-small cell lung cancer (NSCLC), sponsored by Immuneering Corporation. Started Oct 2022; status: active, not recruiting.
02
Drugs
atebimetinib
03
Conditions
solid tumorpancreatic adenocarcinoma (PDAC)melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05585320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05585320.